Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel
OTCMKTS:ALPMY

Astellas Pharma Q4 2025 Earnings Results & Report

Astellas Pharma logo
$14.39 +0.04 (+0.28%)
As of 03:59 PM Eastern

Astellas Pharma beat analyst expectations on both earnings and revenue in its Q4 2025 results, released April 25, 2025. The company reported EPS of $0.27 versus the $0.1474 consensus estimate, while revenue of $3.22 billion topped the $3.02 billion estimate by $205.66 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
Before Market Opens

Astellas Pharma EPS Results

Actual EPS
$0.27
Consensus EPS
$0.1474
Beat/Miss
Beat by +$0.1226
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 7 quarters

Astellas Pharma Revenue Results

Actual Revenue
$3.22 billion
Expected Revenue
$3.02 billion
Beat/Miss
Beat by +$205.66 million
YoY Revenue Growth
N/A

Upcoming Earnings

Astellas Pharma's next earnings date is estimated for Wednesday, November 4, 2026, based on past reporting schedules.

Conference Call Resources

Astellas Pharma Q4 2025 Earnings FAQ

Astellas Pharma (OTCMKTS:ALPMY) reported earnings of $0.27 per share for Q4 2025, beating the consensus estimate of $0.1474. The report was announced on Friday, April 25, 2025.

Astellas Pharma reported revenue of $3.22 billion for Q4 2025, against a consensus estimate of $3.02 billion.

Astellas Pharma's next earnings date is estimated for Wednesday, November 4, 2026. MarketBeat tracks confirmed and estimated earnings dates for Astellas Pharma on the company's earnings history page.

Astellas Pharma Earnings Headlines

Astellas Pharma (OTCMKTS:ALPMY) Shares Gap Down - Here's What Happened
October 12 at 11:21 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31111214
Astellas Pharma Inc. (OTCMKTS:ALPMY) Stock Short Interest Rises 519.9%
October 10 at 3:01 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31105027
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel
October 13 at 1:00 AM  |  Weiss Ratings (Ad)
Head-To-Head Contrast: Heron Therapeutics (NASDAQ:HRTX) vs. Astellas Pharma (OTCMKTS:ALPMY)
October 9, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31102625
Astellas Pharma (OTCMKTS:ALPMY) Shares Gap Up - Here's Why
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31082967
Mizuho Securities Sticks to Their Hold Rating for Astellas Pharma (ALPMF)
September 15, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ALPMY/pressreleases/4605861/mizuho-securities-sticks-to-their-hold-rating-for-astellas-pharma-alpmf/
See More Astellas Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Astellas Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Astellas Pharma and other key companies, straight to your email.

About Astellas Pharma

Astellas Pharma (OTCMKTS:ALPMY) is a Japan-based pharmaceutical company that researches, develops, manufactures and commercializes prescription medicines for patients worldwide. Its portfolio focuses on areas of significant unmet medical need, including oncology, immunology, urology, ophthalmology, neuroscience and medical conditions related to genetic regulation.

The company’s products include XTANDI (enzalutamide) for certain prostate cancers, XOSPATA (gilteritinib) for acute myeloid leukemia, PADCEV (enfortumab vedotin-ejfv) for certain urothelial cancers, and PROGRAF (tacrolimus), an immunosuppressant used primarily to help prevent organ rejection following transplantation. Astellas also develops medicines and investigational therapies through internal research and collaborations with biotechnology and pharmaceutical companies.

Astellas was established in 2005 through the merger of Yamanouchi Pharmaceutical Co. and Fujisawa Pharmaceutical Co., two Japanese companies with histories dating back several decades. Headquartered in Tokyo, the company serves markets across North America, Europe, Asia and other regions through a global research, development and commercial organization. Naoki Okamura serves as Astellas Pharma’s president and chief executive officer.

View Astellas Pharma Profile
Earnings Tools